Fluoxetine: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Repoint CYP2D6/CYP3A4 links to the new Enzyme: namespace |
MDElliottMD (talk | contribs) Link legal-status field to the USLegal: namespace |
||
| Line 19: | Line 19: | ||
| bioavailability = 70–90% (oral) | | bioavailability = 70–90% (oral) | ||
| pregnancy = Category C<ref name="lactmed">S0</ref> | | pregnancy = Category C<ref name="lactmed">S0</ref> | ||
| legal = Rx-only in US | | legal = [[USLegal:Prescription only|Rx-only]] in US | ||
| mechanism = TrkB/BDNF<ref name="trkb">S1</ref> <vote slug="ssri-claim">Fluoxetine is a selective serotonin reuptake inhibitor.</vote> | | mechanism = TrkB/BDNF<ref name="trkb">S1</ref> <vote slug="ssri-claim">Fluoxetine is a selective serotonin reuptake inhibitor.</vote> | ||
| intro = Fluoxetine, marketed as Prozac, was the first selective serotonin reuptake inhibitor ([[:Category:Selective_Serotonin_Reuptake_Inhibitors_(SSRIs)|SSRIs]]) brought to market and the medicine that opened the SSRI era. It was discovered at Eli Lilly's laboratories in Indianapolis on 24 July 1972 by a team that included the chemists Bryan Molloy and Klaus Schmiegel and the pharmacologist David Wong,<ref name="wong1974">Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sciences. 1974;15(3):471-479. PMID: 4549929.</ref> approved by the FDA in December 1987, and launched in the United States as Prozac in January 1988. It is notable for the extremely long half-life of its active metabolite norfluoxetine, which gives the medicine an unusually mild discontinuation profile and makes it useful as a bridge in tapering patients off shorter-acting serotonergic medicines. | | intro = Fluoxetine, marketed as Prozac, was the first selective serotonin reuptake inhibitor ([[:Category:Selective_Serotonin_Reuptake_Inhibitors_(SSRIs)|SSRIs]]) brought to market and the medicine that opened the SSRI era. It was discovered at Eli Lilly's laboratories in Indianapolis on 24 July 1972 by a team that included the chemists Bryan Molloy and Klaus Schmiegel and the pharmacologist David Wong,<ref name="wong1974">Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sciences. 1974;15(3):471-479. PMID: 4549929.</ref> approved by the FDA in December 1987, and launched in the United States as Prozac in January 1988. It is notable for the extremely long half-life of its active metabolite norfluoxetine, which gives the medicine an unusually mild discontinuation profile and makes it useful as a bridge in tapering patients off shorter-acting serotonergic medicines. | ||